CD8A and Autoimmunity: Beyond the safety and efficacy of GUCY2C vaccination, preclinical studies in mice demonstrated that self-tolerance, which limits the production of immune responses to self proteins and subsequent autoimmunity, reduced vaccine-induced CD8+ T-cell responses to GUCY2C, and eliminated GUCY2C-specific antibody and CD4+ T-cell responses [18–20].